ImmunityBio Statistics

Total Valuation

ImmunityBio has a market cap or net worth of $2.37 billion. The enterprise value is $3.01 billion.

Market Cap	2.37B
Enterprise Value	3.01B

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

ImmunityBio has 882.47 million shares outstanding. The number of shares has increased by 37.71% in one year.

Current Share Class	882.47M
Shares Outstanding	882.47M
Shares Change (YoY)	+37.71%
Shares Change (QoQ)	+5.24%
Owned by Insiders (%)	33.50%
Owned by Institutions (%)	10.04%
Float	233.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	127.22
Forward PS	19.16
PB Ratio	-4.86
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	204.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.36

Current Ratio	3.36
Quick Ratio	2.77
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.23

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-48.48%
Return on Invested Capital (ROIC)	-71.77%
Return on Capital Employed (ROCE)	-104.94%
Revenue Per Employee	$21,684
Profits Per Employee	-$608,182
Employee Count	680
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.55% in the last 52 weeks. The beta is -0.13, so ImmunityBio's price volatility has been lower than the market average.

Beta (5Y)	-0.13
52-Week Price Change	-45.55%
50-Day Moving Average	2.95
200-Day Moving Average	3.81
Relative Strength Index (RSI)	47.90
Average Volume (20 Days)	7,988,047

Short Selling Information

The latest short interest is 63.18 million, so 7.16% of the outstanding shares have been sold short.

Short Interest	63.18M
Short Previous Month	59.54M
Short % of Shares Out	7.16%
Short % of Float	27.02%
Short Ratio (days to cover)	10.24

Income Statement

In the last 12 months, ImmunityBio had revenue of $14.75 million and -$413.56 million in losses. Loss per share was -$0.62.

Revenue	14.75M
Gross Profit	14.75M
Operating Income	-344.18M
Pretax Income	n/a
Net Income	-413.56M
EBITDA	-326.63M
EBIT	-344.18M
Loss Per Share	-$0.62

Full Income Statement

Balance Sheet

The company has $149.81 million in cash and $789.82 million in debt, giving a net cash position of -$640.01 million or -$0.73 per share.

Cash & Cash Equivalents	149.81M
Total Debt	789.82M
Net Cash	-640.01M
Net Cash Per Share	-$0.73
Equity (Book Value)	-488.13M
Book Value Per Share	-0.57
Working Capital	129.64M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$391.24 million and capital expenditures -$6.89 million, giving a free cash flow of -$398.12 million.

Operating Cash Flow	-391.24M
Capital Expenditures	-6.89M
Free Cash Flow	-398.12M
FCF Per Share	-$0.45

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-2,334.24%
Pretax Margin	-2,805.32%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ImmunityBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-37.71%
Shareholder Yield	-37.71%
Earnings Yield	-17.42%
FCF Yield	-16.77%

Analyst Forecast

The average price target for ImmunityBio is $11.35, which is 321.93% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.35
Price Target Difference	321.93%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	173.00%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ImmunityBio has an Altman Z-Score of -12.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.5
Piotroski F-Score	3